Sophie Gardrat

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Divergent local and systemic antitumor response in primary uveal melanomas.

Divergent local and systemic antitumor response in primary uveal melanomas.

Journal: The Journal of experimental medicine
Published: November 14, 2023

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Journal: Current oncology (Toronto, Ont.)
Published: August 14, 2023

Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.

Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.

Journal: JCO precision oncology
Published: May 24, 2023

Intraocular Invasion by Conjunctival Squamous Cell Carcinoma: Clinical Presentation, Histopathological Findings, and Outcome.

Intraocular Invasion by Conjunctival Squamous Cell Carcinoma: Clinical Presentation, Histopathological Findings, and Outcome.

Journal: Ocular oncology and pathology
Published: April 10, 2023

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.

Journal: Cancers
Published: March 03, 2023

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.

Journal: Annals of surgery
Published: February 27, 2023

Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.

Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.

Journal: British journal of cancer
Published: February 08, 2023

Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma.

Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma.

Journal: Annals of surgical oncology
Published: May 13, 2022

Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency.

Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency.

Journal: NPJ precision oncology
Published: March 30, 2022

L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases.

L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases.

Journal: Laboratory investigation; a journal of technical methods and pathology
Published: March 10, 2022

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 01, 2022

EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia.

EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia.

Journal: Diagnostics (Basel, Switzerland)
Published: February 22, 2022
Showing 1-12 of 32

Last Updated: 09/26/2026